Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 184.87M P/E - EPS this Y 5.50% Ern Qtrly Grth -
Income -48.82M Forward P/E -5.04 EPS next Y 102.30% 50D Avg Chg -9.00%
Sales 81k PEG - EPS past 5Y - 200D Avg Chg -27.00%
Dividend N/A Price/Book 3.15 EPS next 5Y - 52W High Chg -54.00%
Recommedations 2.00 Quick Ratio 9.03 Shares Outstanding 29.40M 52W Low Chg 35.00%
Insider Own 2.16% ROA -33.17% Shares Float 28.61M Beta 0.08
Inst Own 24.57% ROE -94.92% Shares Shorted/Prior 2.19M/1.80M Price 7.00
Gross Margin 100.00% Profit Margin - Avg. Volume 222,606 Target Price 25.47
Oper. Margin -12,769.14% Earnings Date May 15 Volume 107,766 Change -1.96%
About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.

Actinium Pharmaceuticals, Inc. News
04/01/24 Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
03/26/24 Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
03/15/24 High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment
03/11/24 Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
02/26/24 Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
02/25/24 7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
02/23/24 Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
01/02/24 Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
12/11/23 Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
12/11/23 Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
12/08/23 Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
11/06/23 Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
11/02/23 Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
11/02/23 Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
10/31/23 Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
10/04/23 Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
09/27/23 Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
09/07/23 Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO
08/31/23 Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting
08/21/23 Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress
ATNM Chatroom

User Image dm4 Posted - 4 minutes ago

$ATNM https://x.com/aml_hub/status/1780564378783289835?s=46&t=OgLhSpWTIRlbsCZBSb2a-w

User Image Tomaxx131 Posted - 1 hour ago

$ATNM No matter how annoying things drop on me, I will hold my ATNM shares like a baby.

User Image Shinshaker Posted - 1 hour ago

$ATNM sick of this shit. Originally q4….then 1h 2024…now it’s gonna be q3 2024.

User Image WizeKing44 Posted - 1 hour ago

$ATNM What is Seth waiting on…..

User Image Biotrad3r Posted - 3 hours ago

$ATNM Anyone who doesn't think this is all a part of a coordinated large scale effort is full of it. This is all part of some group's effort for the past 2 months. Just look at the chart at its easy to see the cycle. Large Short attacks and/or MM manipulation Mid-month, end-of-month, mid-month, for accumulation of cheap shares. SEC is going to discover this eventually and 10 to 1 says MM is involved... https://www.investopedia.com/terms/s/shakeout.asp

User Image phaa Posted - 4 hours ago

$ATNM What happened to the abnormal high trading volume over the last couple of weeks? Do your due diligence, look for previuos days of abnormal trade volume, compare it to what happened with the price of the stock during the abnormal high volume. What happened to the price of the stock once trade volume went back to the average? Do your due diligence, ask questions.

User Image AAVIE Posted - 5 hours ago


User Image Kittinvestments Posted - 5 hours ago

$ATNM frustrated… but fundamentally nothing has changed. BLA will be submitted sometime this year, both here and in the EU (I’m expecting a delay submission to FDA to Q3-4). But 2025 iomab will be approved and start commercialization. Immedica will be instrumental for revenue (they are more competent than Seth). And Buy Out is still a strong possibility any time! Either way, if no BO, ATNM is meant to be worth $4-5B by 2028-29.

User Image BabbeL1104 Posted - 5 hours ago

$ATNM no bids anywhere in this market , not just ATNM. High inflation, rising rates , wars abound

User Image SageSpirits Posted - 5 hours ago


User Image Roseyposey Posted - 5 hours ago

$ATNM That’s right, I added. #20B Bo Baby!!!

User Image Pickerbefore Posted - 5 hours ago

$ATNM the CEO must have pulled another Seth and everyone knows it. At least he is consistent and screwing up This fool is bad.

User Image ImCrazy Posted - 6 hours ago

$ATNM 12:39 PM Wednesday, in Scotland, UK is 6:39 AM Wednesday, in Austin, TX

User Image Nibbler Posted - 7 hours ago

$ATNM Wen buyout?

User Image kmers_bossman Posted - 7 hours ago

$ATNM yikes down 20% this week alone is there a reason for this price action? Might add some more below 7

User Image DWTW Posted - 8 hours ago

$ATNM Nothing new or earth shattering but something to pass the time. https://www.openpr.com/news/3467144/actinium-pharmaceuticals-atnm-garners-attention-with

User Image beerjetz Posted - 8 hours ago

$ATNM By the way, why has this company been passed over for a buyout by many other early stage companies? Asking @Biotrad3r @gbtrade @AAVIE @GwilliamG @buynhold1 @Investfaithfully @englishkaren @Musubi and the rest of the accounts, of the lone, paid pumper. 🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣

User Image Biotrad3r Posted - 8 hours ago

$ATNM By the way, how many warrants and options expire in two days? 🤔

User Image englishkaren Posted - 8 hours ago

$ATNM interesting - Unprecedented $399.8M federal investment in TRIUMF advances Canadian science and innovation https://www.newswire.ca/news-releases/unprecedented-399-8m-federal-investment-in-triumf-advances-canadian-science-and-innovation-887929327.html

User Image HiNoobie Posted - 8 hours ago

$ATNM Unpopular opinion: Seth is extremely UNDERPAID!

User Image EFhutton420 Posted - 8 hours ago

$ATNM ☺️

User Image Investfaithfully Posted - 9 hours ago

$ATNM great time to get in newbies!

User Image EFhutton420 Posted - 9 hours ago

$ATNM in Seth We Trust. Truly.

User Image EFhutton420 Posted - 9 hours ago


User Image janlukas Posted - 9 hours ago

$ATNM This drop makes me think of some dilution on the way even though it would have been more logical when it was above $9.

User Image gooddoggie Posted - 10 hours ago

$ATNM Last gasp of the downers. Will close green (I think). In the meantime, I’ve got something warming up in the kitchen!

User Image tjm1 Posted - 10 hours ago

$ATNM Oh my! Bet this doesn't deter Seth depositing his $36k weekly comp.

User Image anthonyjacobs Posted - 10 hours ago

$ATNM Stock has been down i guess bad news?

User Image beerjetz Posted - 10 hours ago

$ATNM HELLOOOOOO AAVIE!!!!!!!! $2 AS SOON!!!!!!!!!🚀🚀🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣

User Image Biotrad3r Posted - 10 hours ago

$ATNM Classic retail shake out. Somebody wants your cheap shares badly! Longs here have seen much worse. Always a dip before the rip.

Analyst Ratings
HC Wainwright & Co. Buy Apr 1, 24
Cantor Fitzgerald Overweight Apr 1, 24
HC Wainwright & Co. Buy Mar 26, 24
Maxim Group Buy Mar 19, 24
HC Wainwright & Co. Buy Mar 19, 24
HC Wainwright & Co. Buy Mar 11, 24
B. Riley Securities Buy Dec 11, 23
B. Riley Securities Buy Oct 3, 23
HC Wainwright & Co. Buy Sep 7, 23